Dupuytren's contracture is a thickening and shortening ... However, as with nonsurgical treatments, the contracture can come back, so some people may need additional surgery later on.

which may contribute to the persistence of the contracture. This highlights the importance of understanding the underlying tissue characteristics in developing effective treatment strategies[3].

NICE originally rejected Xiapex (collagenase clostridium histolyticum) from Swedish Orphan Biovitrum (SOBI) back in 2013, the first pharmacological treatment for Dupuytren’s contracture.